



Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. *Blood*. 2023;142(2):141-145.

Page 144, left column, lines 2 and 3 of the main text: The sentence “Four patients (7.5%) discontinued treatment because of treatment-related AE” should read “Four patients (7.5%) interrupted treatment because of treatment-related AE.”

<https://doi.org/10.1182/blood.2024024192>

© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Downloaded from http://ashpublications.org/blood/article-pdf/143/13/1622/18711/blood_bld-2024-024192-main.pdf by guest on 27 June 2024